NK Cell-based Therapy Development Service for Bladder Cancer
Natural killer (NK) cells, a subset of immune effector cells known for their potent anti-viral and anti-tumor activity, have recently emerged as a promising candidate for cancer immunotherapy. Alfa Cytology is dedicated to providing innovative services in the development of NK cell therapy specifically tailored for bladder cancer.
Introduction to NK Cell-based Therapy
Natural killer cell therapy is a form of cellular immunotherapy, similar to CAR T-cell therapy. Like T-cells, NK cells are integral components of the immune system and exhibit cytotoxicity against pathogens and malignant cells. However, unlike T-cells, NK cells possess a non-specific antigen recognition capability, functioning as versatile effectors capable of identifying and eliminating aberrant cells. Occasionally, NK cells may be engineered with chimeric antigen receptors (CARs) to enhance their specificity towards cancerous cells. The operational mechanism of NK cells is as follows.
- Recognition and Killing of Cancer Cells
NK cells recognize infected or cancerous cells through activating and inhibitory receptors on their surface. Once an abnormal cell is identified, NK cells release perforins and granzymes, which disrupt the target cell membrane and induce apoptosis.
- Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
NK cells enhance their cytotoxic activity by binding to antibody-coated cancer cells. This process relies on the FcγRIII receptor on the surface of NK cells.
- Cytokine Secretion
Upon activation, NK cells secrete various cytokines, such as IFN-γ and TNF-α, which can enhance the immune system's anti-tumor response.
Fig.1. Methods of NK cell-based immunotherapy for cancer. (Shin, M. H., et al., 2020)
Our Services
At the forefront of cancer treatment, NK cell-based therapies are gaining attention for their unique anti-tumor capabilities. As a preclinical contract research organization (CRO) company specializing in bladder cancer research, Alfa Cytology offers comprehensive NK cell-based therapy development services to support researchers and pharmaceutical companies in advancing the development and translation of new therapies.
NK Cell Isolation and Purification
We offer efficient NK cell isolation and purification services, ensuring high purity and activity of NK cells for further experimental use.
Genetic Engineering of NK Cells
Leveraging cutting-edge tools like CRISPR/Cas9 and viral vectors, we precisely modify NK cell genomes. This allows us to introduce or edit genes, enhancing cytotoxicity, improving persistence, or imparting novel functionalities crucial for effective tumor targeting.
In Vitro Expansion of NK Cells
Our optimized culture conditions and specific cytokine additions significantly expand NK cell numbers while maintaining their functionality.
Functional Evaluation of NK Cells
Comprehensive functional assessments include:
- Cytotoxicity Assays
Evaluating NK cell killing activity against bladder cancer cells.
- Cytokine Secretion Analysis
Measuring the production of key cytokines like IFN-γ and TNF-α.
- Phenotypic Analysis
Using flow cytometry to assess NK cell activation markers.
In Vivo Bladder Cancer Models
We utilize various bladder cancer animal models to validate the efficacy of NK cell therapies, including:
- Tumor Growth Inhibition Studies
Assessing the impact of NK cell therapy on tumor growth.
- Survival Analysis
Investigating the effects of NK cell treatment on the survival rates of animal models.
We conduct thorough toxicology studies, including acute and chronic toxicity tests, to ensure the safety of NK cell therapies.
Data Analysis and Reporting
Our comprehensive data analysis services include statistical analysis and detailed technical reports, providing clients with actionable insights for their research.
Contact Us
If you are interested in our NK cell-based therapy development services for bladder cancer, please
contact us. We look forward to collaborating with you to advance bladder cancer therapy.
Reference
- Shin, M. H., Kim, J., and et al. NK Cell-Based Immunotherapies in Cancer. Immune network, 2020, 20(2), e14.
For research use only. Not intended for any clinical use.
Related Services
